Underuse of aldosterone antagonists in systolic CHF

In this analysis of a large cardiovascular registry, of the patients with moderate to severe systolic CHF who were eligible for aldosterone antagonist therapy, only 1/3 received it at discharge. Many patients eligible for aldosterone antagonist therapy do not receive it (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment